ArticleJournal of the American Geriatrics Society2011
Angiotensin-converting enzyme inhibitor and statin use and incident mobility limitation in community-dwelling older adults: the Health, Aging and Body Composition study.
Article in Journal of the American Geriatrics Society, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- The effect of statins on falls and physical activity in people aged 65 and older: A systematic review.European journal of clinical pharmacology · 2024Pooled it
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Circulation · 2019 · on this mapGuideline
- 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.Circulation · 2014 · on this mapGuideline
- Supplements and Drugs Are Associated With Biological Age in a Cohort of Exceptionally Healthy Individuals.Aging cell · 2026Article
- Associations Between Hypertension, Angiotensin-Converting Enzyme Inhibitors, and Physical Performance in Very Old Adults: Results from the ilSIRENTE Study.The Journal of frailty & aging · 2024Article
- A comparative analysis of selective serotonin reuptake inhibitors and fall risk in older adults.Journal of the American Geriatrics Society · 2022Article
- Effects of Statins for Secondary Prevention on Functioning and Other Outcomes Among Nursing Home Residents.Journal of the American Medical Directors Association · 2020Article
- Associations between ACE-Inhibitors, Angiotensin Receptor Blockers, and Lean Body Mass in Community Dwelling Older Women.Journal of aging research · 2018Article
- Guideline-Recommended Medications and Physical Function in Older Adults with Multiple Chronic Conditions.Journal of the American Geriatrics Society · 2017Observational
- Deprescribing in Older Nursing Home Patients: Focus on Innovative Composite Measures for Dosage Deintensification.Innovation in aging · 2017Review
- ARB users exhibit a lower fracture incidence than ACE inhibitor users among older hypertensive men.Age and ageing · 2017Observational
- Statin use and decline in gait speed in community-dwelling older adults.Journal of the American Geriatrics Society · 2015Article
- Atherosclerotic Cardiovascular Disease Risk and Evidence-based Management of Cholesterol.North American journal of medical sciences · 2014Review
- Lipid-lowering drugs associated with slower motor decline in the elderly adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2014Article
- Article
- Statins, angiotensin-converting enzyme inhibitors, and physical performance in older women.Journal of the American Geriatrics Society · 2012Article
- FRAILTY: A Report from the 3(rd) Joint Workshop of IAGG/WHO/SFGG, Athens, January 2012.Canadian geriatrics journal : CGJ · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
Abstract
objectivesTo evaluate whether the use of angiotensin-converting enzyme (ACE) inhibitors and statins is associated with a lower risk of incident mobility limitation in older community dwelling adults.
designLongitudinal cohort study.
settingHealth, Aging and Body Composition (Health ABC) study.
participantsThree thousand fifty-five participants who were well functioning at baseline (no mobility limitations). MEASUREMENTS: Summated standardized daily doses (low, medium, high) and duration of ACE inhibitor and statin use were computed. Mobility limitation (two consecutive self-reports of having any difficulty walking one-quarter of a mile or climbing 10 steps without resting) was assessed every 6 months after baseline. Multivariable Cox proportional hazards analyses were conducted, adjusting for demographics, health status, and health behaviors.
resultsAt baseline, 15.2% used ACE inhibitors and 12.9% used statins; use of both was greater than 25% by Year 6. Over 6.5 years of follow-up, 49.8% had developed mobility limitation. In separate multivariable models, neither ACE inhibitor (multivariate hazard ratio (HR) = 0.95, 95% confidence interval (CI) = 0.82-1.09) nor statin use (multivariate HR = 1.02, 95% CI = 0.87-1.17) was associated with lower risk of mobility limitation. Similar findings were seen in analyses examining dose-response and duration-response relationships and a sensitivity analysis restricted to those with hypertension.
conclusionACE inhibitors and statins widely prescribed to treat hypertension and hypercholesterolemia, respectively, do not lower risk of mobility limitation, an important indicator of quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.